Payam Nahid, MD, MPH

Professor

Dr. Nahid is Professor in Residence in the Division of Pulmonary and Critical Care Medicine, Director of the UCSF Center for Tuberculosis (https://tb.ucsf.edu), Associate Director of Clinical Trials Operations in the UCSF Office of Research, and Medical Director of the UCSF CTSA Trials Innovation Network Hub. His research includes the conduct of clinical trials and translational research in TB with the goal of improving the care of patients with TB and HIV/TB worldwide. Dr. Nahid leads NIH and CDC-funded field studies of new TB diagnostics, Phase 2 and 3 clinical trials in TB therapeutics and latent TB infection treatment implementation studies in partnership with the Vietnam National TB Program, the Vietnam National Lung Hospital, the Hanoi Lung Hospital, Cho Ray Hospital and the Vietnam National Institute of Hygiene and Epidemiology. Dr. Nahid also oversees NIH and BMGF-funded TB biomarker discovery and qualification programs to identify improved biomarkers of treatment effect. Dr. Nahid serves as Chair of the CDC-TBTC Core Science Group and has led the WHO Task Force for New TB Drugs and Treatment Regimens. He leads and has contributed to the development of U.S. and international practice guidelines for the treatment of TB, and provides clinical TB consultation and trainings as part of the UCSF Curry International TB Center of Excellence.
Education
M.P.H., 2004 - Epidemiology, San Diego State University
Fellowship, 2004 - Pulmonary and Critical Care Medicine, University of California, San Francisco
Residency, 2001 - Internal Medicine, Scripps Clinic & Research Foundation
M.D., 1997 - School of Medicine, University of California, Irvine
Websites
Publications
  1. Sotgiu G, Battista Migliori G, Menzies D, Mase S, Chorba T, Seaworth B, Nahid P. Reply to: "ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-resistant TB: A Two-edged Sword?" 2020. PMID: 32374628


  2. Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. Identification of Mycobacterium tuberculosis peptides in serum extracellular vesicles from persons with latent tuberculosis infection. 2020. PMID: 32245831


  3. Cegielski JP, Nahid P, Sotgiu G. The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis. Volume 55 of Issue 3. 2020. PMID: 32198274


  4. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Volume 8 of Issue 4. 2020. PMID: 32192585


  5. Thwaites G, Nahid P. Triumph and Tragedy of 21st Century Tuberculosis Drug Development. Volume 382 of Issue 10. 2020. PMID: 32130819


  6. Lienhardt C, Nunn A, Chaisson R, Vernon AA, Zignol M, Nahid P, Delaporte E, Kasaeva T. Advances in clinical trial design: Weaving tomorrow's TB treatments. Volume 17 of Issue 2. 2020. PMID: 32106220


  7. Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. 2020. PMID: 31981713


  8. Andrew Vernon, Katherine Fielding, Rada Savic, Lori Dodd, Payam Nahid. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. 2019. PMID:


  9. Vernon A, Fielding K, Savic R, Dodd L, Nahid P. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. Volume 16 of Issue 12. 2019. PMID: 31821323


  10. Zha BS, Nahid P. Treatment of Drug-Susceptible Tuberculosis. Volume 40 of Issue 4. 2019. PMID: 31731983


  11. Blount RJ, Pascopella L, Barry P, Zabner J, Stapleton EM, Flood J, Balmes J, Nahid P, Catanzaro DG. Residential urban tree canopy is associated with decreased mortality during tuberculosis treatment in California. 2019. PMID: 32000313


  12. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. 2019. PMID: 31729908


  13. Robert J. Blount, Lisa Pascopella, Pennan Barry, Joseph Zabner, Emma Stapleton, Jennifer Flood, John Balmes, Payam Nahid, Donald G. Catanzaro. Residential urban tree canopy is associated with decreased mortality during tuberculosis treatment in California. 2019. PMID:


  14. Lienhardt C, Vernon AA, Cavaleri M, Nambiar S, Nahid P. Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance. Volume 16 of Issue 9. 2019. PMID: 31490921


  15. Menzies D, Benedetti A, Migliori GB, Nahid P, Seaworth B. Multidrug-resistant tuberculosis - Authors' reply. Volume 394 of Issue 10195. 2019. PMID: 31354139


  16. Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P. Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. 2019. PMID: 31151255


  17. Broger T, Tsionksy M, Mathew A, Lowary TL, Pinter A, Plisova T, Bartlett D, Barbero S, Denkinger CM, Moreau E, Katsuragi K, Kawasaki M, Nahid P, Sigal GB. Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients. Volume 14 of Issue 4. 2019. PMID: 30998715


  18. Lienhardt C, Nahid P. Advances in clinical trial design for development of new TB treatments: A call for innovation. Volume 16 of Issue 3. 2019. PMID: 30901322


  19. Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ. Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. 2019. PMID: 30901331


  20. Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Hoi LV, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P. Moving Toward Tuberculosis Elimination: Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. 2018. PMID: 30335466


  21. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. 2019. PMID: 30429542


  22. Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, Tsionsky M, Zheng RB, Plisova T, Shen K, Katsuragi K, Choudhary A, Honnen WJ, Nahid P, Denkinger CM, Broger T. A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis. Volume 56 of Issue 12. 2018. PMID: 30257899


  23. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. 2018. PMID: 30397355


  24. Korkmaz Ekren P, Töreyin ZN, Nahid P, Doskaya M, Caner A, Turgay N, Zeytinoglu A, Toz S, Bacakoglu F, Guruz Y, Erensoy S. The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients. Volume 12 of Issue 11. 2018. PMID: 30244544


  25. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Volume 392 of Issue 10150. 2018. PMID: 30215381


  26. Robert Blount, Payam Nahid, Adithya Cattamanchi. Tuberculosis. 2018. PMID:


  27. Kedia K, Wendler JP, Baker ES, Burnum-Johnson KE, Jarsberg LG, Stratton KG, Wright AT, Piehowski PD, Gritsenko MA, Lewinsohn DM, Sigal GB, Weiner MH, Smith RD, Jacobs JM, Nahid P. Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis. Volume 112. 2018. PMID: 30205969


  28. Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. Volume 15 of Issue 7. 2018. PMID: 29969463


  29. Walter ND, Moore CM, Kayigire XA, Dide-Agossou C, Worodria W, Huang L, Everett CK, Schoolnik GS, Nahid P, Davis JL. Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputum. 2018. PMID: 29970012


  30. Nahid P, Jarlsberg LG, Kato-Maeda M, Segal MR, Osmond DH, Gagneux S, Dobos K, Gold M, Hopewell PC, Lewinsohn DM. Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis. 2018. PMID: 29787561


  31. Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, Small N, Haynesworth K, Davis JL, Weiner M, Whitworth WC, Jacobs J, Schorey J, Lewinsohn DM, Nahid P. Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial. Volume 25. 2017. PMID: 29100778


  32. Blount RJ, Pascopella L, Catanzaro DG, Barry PM, English PB, Segal MR, Flood J, Meltzer D, Jones B, Balmes J, Nahid P. Traffic-Related Air Pollution and All-Cause Mortality during Tuberculosis Treatment in California. Volume 125 of Issue 9. 2017. PMID: 28963088


  33. Feng JY, Jarlsberg LG, Salcedo K, Rose J, Janes M, Lin SG, Osmond DH, Jost KC, Soehnlen MK, Flood J, Graviss EA, Desmond E, Moonan PK, Nahid P, Hopewell PC, Kato-Maeda M. Clinical and bacteriological characteristics associated with clustering of multidrug-resistant tuberculosis. 2017. PMID: 28513421


  34. Feng JY, Jarlsberg LG, Rose J, Grinsdale JA, Janes M, Higashi J, Osmond DH, Nahid P, Hopewell PC, Kato-Maeda M. Impact of Euro-American sublineages of Mycobacterium tuberculosis on new infections among named contacts. 2017. PMID: 28399965


  35. Salepci B, Caglayan B, Nahid P, Parmaksiz ET, Kiral N, Fidan A, Comert SS, Dogan C, Gungor GA. Vitamin D Deficiency in Patients Referred for Evaluation of Obstructive Sleep Apnea. Volume 13 of Issue 4. 2017. PMID: 27998376


  36. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. 2017. PMID: 28344011


  37. Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Volume 102 of Issue 2. 2017. PMID: 28124478


  38. Zhou XY, Jeffris KE, Yu EY, Zheng B, Goodwill PW, Nahid P, Conolly SM. First in vivo magnetic particle imaging of lung perfusion in rats. Volume 62 of Issue 9. 2017. PMID: 28218614


  39. Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M. Target regimen profiles for treatment of tuberculosis: a WHO document. Volume 49 of Issue 1. 2017. PMID: 28122858


  40. Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. Volume 14 of Issue 1. 2017. PMID: 28045934


  41. Payam Nahid, Philip C. Hopewell. Tuberculosis Treatment. 2017. PMID:


  42. Dela Cruz CS, Lyons PG, Pasnick S, Weinstock T, Nahid P, Wilson KC, Thomson CC. Treatment of Drug-Susceptible Tuberculosis. Volume 13 of Issue 11. 2016. PMID: 27831799


  43. Alipanah N, Cattamanchi A, Menzies R, Hopewell PC, Chaisson RE, Nahid P. Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis. 2016. PMID: 27776595


  44. Peloquin CA, Dorman SE, Vernon A, Battista Migliori G, Nahid P. Reply to Alffenaar et al. Volume 64 of Issue 1. 2016. PMID: 27789610


  45. Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P. Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure. Volume 54 of Issue 12. 2016. PMID: 27733634


  46. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Volume 63 of Issue 7. 2016. PMID: 27621353


  47. Sotgiu G, Nahid P, Loddenkemper R, Abubakar I, Miravitlles M, Migliori GB. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Volume 48 of Issue 4. 2016. PMID: 27587550


  48. Blount RJ, Tran MC, Everett CK, Cattamanchi A, Metcalfe JZ, Connor D, Miller CR, Grinsdale J, Higashi J, Nahid P. Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. Volume 16 of Issue 1. 2016. PMID: 27558397


  49. Walter ND, de Jong BC, Garcia BJ, Dolganov GM, Worodria W, Byanyima P, Musisi E, Huang L, Chan ED, Van TT, Antonio M, Ayorinde A, Kato-Maeda M, Nahid P, Leung AM, Yen A, Fingerlin TE, Kechris K, Strong M, Voskuil MI, Davis JL, Schoolnik GK. Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients. 2016. PMID: 27534685


  50. Robert J Blount*, Lisa Pascopella, Pennan Barry, Dan Meltzer, Jenny Flood, Paul B English, Mark R Segal, Payam Nahid, John Balmes, Donald G Catanzaro. Urban tree coverage associated with reduced mortality among tuberculosis (TB) patients undergoing treatment in California. 2016. PMID:


  51. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Volume 63 of Issue 7. 2016. PMID: 27516382


  52. Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). 2016. PMID: 27004726


  53. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. 2016. PMID: 27046707


  54. Dooley KE, Phillips PP, Nahid P, Hoelscher M. Challenges in the clinical assessment of novel tuberculosis drugs. 2016. PMID: 26827911


  55. Nicol MP, Gnanashanmugam D, Browning R, Click ES, Cuevas LE, Detjen A, Graham SM, Levin M, Makhene M, Nahid P, Perez-Velez CM, Reither K, Song R, Spiegel HM, Worrell C, Zar HJ, Walzl G. A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis. Volume 61Suppl 3. 2015. PMID: 26409279


  56. Chaisson LH, Reber C, Phan H, Switz N, Nilsson LM, Myers F, Nhung NV, Luu L, Pham T, Vu C, Nguyen H, Nguyen A, Dinh T, Nahid P, Fletcher DA, Cattamanchi A. Evaluation of mobile digital light-emitting diode fluorescence microscopy in Hanoi, Viet Nam. 2015. PMID: 26260826


  57. Slater M, Tran MC, Platt L, Luu LT, Phan HT, Pham PT, Do TB, Nguyen HT, Gaur RL, Parsonnet J, Cattamanchi A, Luo R, Nahid P, Banaei N. In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection. Volume 83 of Issue 1. 2015. PMID: 26081239


  58. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Volume 95 of Issue 4. 2015. PMID: 26022314


  59. Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunovic A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC. Towards tuberculosis elimination: an action framework for low-incidence countries. Volume 45 of Issue 4. 2015. PMID: 25792630


  60. Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL. Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. Volume 212 of Issue 6. 2015. PMID: 25762787


  61. Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Volume 191 of Issue 3. 2015. PMID: 25489785


  62. Kruh-Garcia NA, Wolfe LM, Chaisson LH, Worodria WO, Nahid P, Schorey JS, Davis JL, Dobos KM. Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS. Volume 9 of Issue 7. 2014. PMID: 25080351


  63. Sheu LC, Tran TM, Jarlsberg LG, Marras TK, Daley CL, Nahid P. Non-tuberculous mycobacterial infections at San Francisco General Hospital. 2014. PMID: 24799125


  64. Blount RJ, Tran B, Jarlsberg LG, Phan H, Thanh Hoang V, Nguyen NV, Lewinsohn DA, Nahid P. Childhood tuberculosis in northern Viet Nam: a review of 103 cases. Volume 9 of Issue 5. 2014. PMID: 24818967


  65. Budzik JM, Jarlsberg LG, Higashi J, Grinsdale J, Hopewell PC, Kato-Maeda M, Nahid P. Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. 2014. PMID: 24759760


  66. Yoon C, Davis JL, Huang L, Muzoora C, Byakwaga H, Scibetta C, Bangsberg DR, Nahid P, Semitala FC, Hunt PW, Martin JN, Cattamanchi A. Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. Volume 65 of Issue 5. 2014. PMID: 24346636


  67. Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Volume 94 of Issue 3. 2014. PMID: 24629635


  68. Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. Volume 3 of Issue 3. 2014. PMID: 26625385


  69. Chang SH, Eitzman SR, Nahid P, Finelli ML. Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents. Volume 7 of Issue 2. 2013. PMID: 24361084


  70. Menzies D, Nahid P. Update in tuberculosis and nontuberculous mycobacterial disease 2012. Volume 188 of Issue 8. 2013. PMID: 24127799


  71. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Volume 12 of Issue 5. 2013. PMID: 23629506


  72. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. Volume 8 of Issue 4. 2013. PMID: 23637781


  73. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A. Drug-resistant tuberculosis: time for visionary political leadership. Volume 13 of Issue 6. 2013. PMID: 23531391


  74. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. Volume 206 of Issue 7. 2012. PMID: 22850121


  75. Nahid P, Menzies D. Update in tuberculosis and nontuberculous mycobacterial disease 2011. Volume 185 of Issue 12. 2012. PMID: 22707733


  76. Dantes R, Metcalfe J, Kim E, Kato-Maeda M, Hopewell PC, Kawamura M, Nahid P, Cattamanchi A. Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. Volume 7 of Issue 5. 2012. PMID: 22649569


  77. Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T, Sizemore C, Stevens WS, Via L, Williams SD, Yew WW, Swindells S. Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. Volume 205 Suppl 2. 2012. PMID: 22476718


  78. Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, Riley LW. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. Volume 92 of Issue 3. 2012. PMID: 22406155


  79. Kato-Maeda M, Nahid P. Mycobacterium tuberculosis lineage--what's in your lungs? 2012. PMID: 22198990


  80. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. 2011. PMID: 21737585


  81. Nahid P, Horne DJ, Jarlsberg LG, Reiner AP, Osmond D, Hopewell PC, Bibbins-Domingo K. Racial differences in tuberculosis infection in United States communities: the coronary artery risk development in young adults study. 2011. PMID: 21765079


  82. Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E, Nahid P, Ferrari G, Stout JE. Discriminating between latent and active tuberculosis with multiple biomarker responses. Volume 91 of Issue 3. 2011. PMID: 21393062


  83. Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. 2011. PMID: 21333096


  84. David J Horne, Sarah E Royce, Masahiro Narita, Payam Nahid, Karen R Steingart. Sputum monitoring during tuberculosis treatment for predicting outcome Authors' reply. 2011. PMID:


  85. Nahid P, Jarlsberg LG, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. 2011. PMID: 21199579


  86. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. 2010. PMID: 20510279


  87. Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. 2010. PMID: 20505778


  88. Kim EY, Nahid P, Hopewell PC, Kato-Maeda M. Novel hot spot of IS6110 insertion in Mycobacterium tuberculosis. 2010. PMID: 20147648


  89. Metcalfe JZ, Cattamanchi A, Vittinghoff E, Ho C, Grinsdale J, Hopewell PC, Kawamura LM, Nahid P. Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects. Volume 181 of Issue 1. 2009. PMID: 19797760


  90. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A. Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Volume 15 of Issue 7. 2009. PMID: 19624921


  91. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, Osmond D, Hopewell PC, Nahid P. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Volume 48 of Issue 2. 2009. PMID: 19086909


  92. Steingart KR, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell PC, Ramsay A, Pai M, Laal S. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. 2008. PMID: 19052159


  93. Cattamanchi A, Nahid P, Marras TK, Gotway MB, Lee TJ, Gonzalez LC, Morris A, Webb WR, Osmond DH, Daley CL. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Volume 133 of Issue 4. 2008. PMID: 18263685


  94. Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B. Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples. Volume 57 of Issue 1. 2008. PMID: 18091290


  95. Payam Nahid, Bouke C. de Jong, Charles L. Daley. On Treatment Outcomes of Patients with HIV and Tuberculosis. 2008. PMID:


  96. Walter ND, Jasmer RM, Grinsdale J, Kawamura LM, Hopewell PC, Nahid P. Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. 2008. PMID: 18171222


  97. P. Nahid, P.C. Hopewell. Tuberculosis Treatment. 2008. PMID:


  98. Adithya Cattamanchi, Payam Nahid. Tuberculosis. 2008. PMID:


  99. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. Treatment outcomes of patients with HIV and tuberculosis. 2007. PMID: 17290042


  100. Chang C, Grush A, McClintock DE, Nahid P, Tang JF. Unusual finding on bronchoscopy: trauma patient identified as a body stuffer. Volume 18 of Issue 8. 2006. PMID: 17175436


  101. Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Volume 10 of Issue 7. 2006. PMID: 16848340


  102. Nahid P, Daley CL. Prevention of tuberculosis in HIV-infected patients. Volume 19 of Issue 2. 2006. PMID: 16514345


  103. Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. 2006. PMID: 16493157


  104. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. 2002. PMID: 12466511